Quantitative Determination of Topiramate in Human Breast Milk
Cristina Cifuentes, Sigrid Mennickent* and Marta De Diego
University of Concepción, Concepción, Chile

Abstract
A thin-layer chromatographic (HPTLC) method for quantification of topiramate in human breast milk was developed using liquid –liquid extraction with n-hexane and methanol as extraction solvents, fluorescence activation with ninhydrine (1% ethanolic solution) and chlorpromazine as internal standard.

Thin-layer chromatographic separation was performed on precoated silica gel F 254 HPTLC plates using a mixture of toluene: ethanol (25:10, v/v), as mobile phase. Densitometric detection was done at 326 nm. The method was validated for linearity, precision, selectivity, LOD and LOQ, and accuracy. Linear calibration curves in the range of 0.30 to 50.00 µg/mL showed correlation coefficient of 0.991. The intra-assay and inter-assay precision, expressed as the relative standard deviation (RSD), were in the range of 3.04% - 3.14% (n=3) and 1.81%-4.10% (n=9), respectively. The limit of detection was 0.24 µg/mL, and the limit of quantification was 0.30 µg/mL. Accuracy, calculated as percentage recovery, was between 101.65% and 109.51%, with a RSD not higher than 0.41%. Topiramate is well resolved from other antiepileptic drugs and from the internal standard (Rs=5.20). In conclusion, the method is precise, accurate, reproducible and selective for the analysis of topiramate in human breast milk.

Keywords: Topiramate; Breast milk; Antiepileptics; Thin-layer chromatography

Introduction
Topiramate (TPM) is a monosaccharide drug with a molecule of fructopyranose in its chemical structure [1] (Figure 1). TPM is an anticonvulsant drug indicated for the treatment and control of partial seizures and severe tonic-clonic (grand mal) seizures in adults [2], including Lennox-Gastant Syndrome in children [3,4]. It is also used for prophylaxis of migraine [5,6], mood instability disorder [7], post-traumatic stress disorder, bulimia nervosa and binge-eating disorders [8]. It is also investigated as promising agent for obesity treatment [9], release of neuropathic pain [10], treatment of sleep related eating disorder [11], alcohol and drug addiction therapy [12,13] and smoking cessation [14-16].

These effects of TPM results from its multiple pharmacological actions, as the enhancement of the activity of γ-aminobutyric acid type A, inhibition of some voltage-gated sodium and calcium channels, inhibition of some glutamate receptors, as well a little inhibition of carbonic anhydrase [17-19].

Food and Drug Administration (FDA) suggest avoid the use of TPM in pregnant woman and in her babies, because the reports of risk oral birth defects (cleft lip and clef palate) in children born to mothers taking TPM (FDA New Release, March 2011). However, sometimes is more difficult to change the antiepileptic drug to some patients, including pregnant women, increasing the risks for their babies.

Some studies shown when the mother was taking 200 mg of topiramate daily had average milk levels of 0.6 µg/mL to 1.2 µg/mL, and these works estimated that the infants received doses between 0.1 and 0.7 mg/kg/day which was between 3 and 23% of the mother’s weight-adjusted dose. Serum levels in a 24-day-old infant whose mother was taking TPM (FDA New Release, March 2011). However, sometimes is more difficult to change the antiepileptic drug to some patients, including pregnant women, increasing the risks for their babies.

Some studies shown when the mother was taking 200 mg of topiramate daily had average milk levels of 0.6 µg/mL to 1.2 µg/mL, and these works estimated that the infants received doses between 0.1 and 0.7 mg/kg/day which was between 3 and 23% of the mother’s weight-adjusted dose. Serum levels in a 24-day-old infant whose mother was taking 200 mg daily had an average serum level of 0.6 µg/mL at 20 days of age and 0.7 µg/mL at 97 days of age. Overall, their plasma levels were about 10 to 20% of maternal plasma levels. Baby blood topiramate concentration is higher as baby age is increased, because the breast –feeding increased too, therefore, the blood concentration of topiramate. Moreover, this drug is a lipophilic compound, increasing its body accumulation [19,20].

The review of literature revealed that TPM has no ultraviolet, visible or fluorescence absorption [21,22]. Analysis of topiramate in pharmaceutical formulation and in biological fluids has been reported by HPLC with pre-column or post column derivatization, and by capillary electrophoresis [23-30], and by LC-MS [31-34]. None method by HPTLC was founded by quantitative determination of TPM in breast milk.

High performance thin-layer chromatography (HPTLC) is a technique carried out within a short period of time, requires few
mobile phase and allows for the analysis of a large number of samples simultaneously. A plate of 10 × 20 cm. allows applying up to 33 spots (27 samples plus standards). HPTLC allows to detect quantities in the order of micrograms and of nanograms (in UV absorbance mode) and smaller than picograms (in fluorescence mode). Therefore, HPTLC allows a fast analysis, with minor cost than other techniques, and with a high selectivity, accuracy and reproducibility.

The developed method can be used to quantitative determination of TPM in human breast milk, suitable for therapeutic drug monitoring of this drug in this matrix, considering as the woman in lactation period as her baby. From these values, could be estimate the baby blood topiramate concentration without the risks to take blood sample from his (her).

**Experimental**

**Instrumentation and reagents**

USP standards of topiramate and chlorpromazine were purchased from Sigma- Aldrich, St. Louis, MO. Methanol, ethanol, toluene and ninhydrine, were obtained from Merck, Darmstadt, Germany. All of the reagents were pro-analysis quality.

**Preparation of standard solutions**

Stock solutions containing 200 µg/mL of TPM were prepared in methanol. Separate solutions were prepared for the calibration standards and quality control samples. These solutions were diluted immediately before use with methanol, to obtain working solutions of 0.3 – 1.2 – 1.4 – 2.0 – 5.0 – 10.0 – 20.0 – 30.0 – 40.0 and 50.0 µg/mL. All of solutions were stored at 4°C for about two days.

**Spiking procedure for calibration and quality control (QC) samples**

The calibration samples were prepared immediately before use by spiking 1 mL of pooled human breast milk with 0.1 mL of a convenient working solution in methanol. Quality control samples were used to determine the intra and inter-assay precision and accuracy of the method. Human breast milk used for the validation of the method was obtained from healthy volunteers.

**Sample preparation**

Human breast milk samples were stored at -20°C until required for analysis. Calibration and quality control samples were thawed at room temperature. Immediately after thawing, 2 mL of sample was processed by adding initially 150 µL of chlorpromazine (internal standard) (50 µg/mL) and 100 µL de NaOH 0.1 M. to the solution, which was subsequently vortexed and centrifuged for 5 minutes at 3000 rpm. Then, the supernatant was transferred to other recipient and 100 µL of methanol was added. Aqueous phase was evaporated under a gentle steam of dry nitrogen at 37°C, and the residue was dissolved in 300 µL of methanol. An aliquot of 1 µL of this solution was spotted for analysis, to obtain the required quantity/spot. All the procedure was accomplished under safety conditions.

**Instrumentation and chromatographic conditions**

The HPTLC system consisted of a TLC Scanner 3 (CAMAG, Muttenz, Switzerland), equipped with software winCATS 1.4.2 (CAMAG); band application device Linomat V (CAMAG); twin trough chromatographic chamber (CAMAG) 10 × 10 cm. and 20 × 10 cm; and HPTLC glass backed plates 10 × 10 cm. and 20 × 10 cm. Precoated with silica gel F 254, layer thickness 0.2 mm (Merck, Darmstadt, Germany), previously washed with methanol and activated at 120°C during 20 minutes.

Serum samples, calibration and quality control samples application volumes were 1 µL of each of them. Sample application was done on 4 mm bands. Number of tracks depended of each assay. Mobile phase consisted of a mixture of toluene: ethanol (25:10, v/v). The chamber was previously saturated. Migration distance was 8 cm. Derivatization of topiramate was done with ninhydrine (1% ethanolic solution), by immersion of the plates into Deeping Device (Camag). This procedure makes topiramate fluorescent and the background dark. Densitometry scanning was performed at 326 nm.

**Stability study**

To establishment the stability of TPM samples, in normal storage conditions, the study was performed as follows: six extractions solutions with derivative agent were used at four different concentrations: 0.3, 1.2 µg/mL, 10 µg/mL and 50 µg/mL. These solutions were storage at three different conditions: freezer temperature, room temperature with light protection, and room temperature without light protection. Concentration determination was evaluated at 0, 1, 4, 7, 11 and 15 days of storage. Each sample was determined by duplicated.

**Method validation**

Validation of developed LC method was carried out as per the International Conference on Harmonization (ICH) guidelines, and as per FDA [33,34].

**Results and Discussion**

During method development different conditions for sample extraction and chromatographic conditions was tried to achieve optimal results.

The selection of the mobile phase was carried out on the basis of polarity i.e., choice a solvent system that would give dense and compact spots with appropriate Rf value, as well as a satisfactory separation of TPM and internal standard and good peak symmetry. Several trials for optimization of mobile phase were taken and finalized as toluene: ethanol (25:10, v/v). This solvent system gave compact spots for topiramate.

Some wavelengths were tried, chosen 326 as working wavelength. Complete resolution of the peaks with clear baseline separation was obtained of this way.

Sample extraction was optimized to eliminate the laborious extraction steps, with minimal losses of carbamazepine and very good recoveries from spiked serum samples.

**Calibration curves**

Calibration curves were constructed over the concentration range of 0.3 to 50.0 µg/mL. Each solution was spotted three times. This range of solution concentrations include the TPM concentrations expected in human breast milk [19,20].

The mean equation (curve coefficients ± standard deviation) for the calibration curve (n=5), obtained from five points, was $y=0.3577x(± 0.1)\,x+0.7893(± 0.2)$ with a correlation coefficient, r=0.99. ANOVA assay showed a relationship between the ratio of peak area of the analyte to the internal standard as a function of the concentration added, with p<0.005.

**Precision and accuracy**

The intra assay precision and accuracy was calculated at low (L), medium (M), and high (H) quality control levels for three replicates each of the same analytical run (each replicate was spotted three times), and inter assay precision and accuracy was calculated after repeated analysis in three different analytical runs.
Each experiment included the sample extraction step. The precision and the accuracy of the assay were measured by the relative standard deviation (RSD) over the concentration range. TPM solutions were of 0.3, 10.0 and 50.0 µg/mL. RSD for intra-assay study was between 3.04% and 3.14%, and for inter-assay was between 1.81% and 4.10%.

Accuracy was calculated from the test results as the percentage of analyte recovered by the assay, determined by linear regression equation of peak area vs. drug concentration. Accuracy was between 101.65% and 109.51%, expressed as analyte recovery percentage. The results are presented in Tables 1 and 2 (precision) and (accuracy) respectively.

Detection and quantification limits

The limit of detection (LOD) and limit of quantification (LOQ) were calculated preparing solutions at three concentrations (0.1-0.2-0.3 µg/mL) in the lower range of linear regression curve for both biological matrices.

LOD was 0.24 µg/mL and LOQ was 0.30 µg/mL, determined using the equations [35,36]: LOD=3.3 σ/b; LOQ=10 σ/b, where σ is the standard deviation of the values, and “b” corresponds to the slope obtained from the curve peak area versus concentration of the analyte. These values were experimentally verified.

Selectivity

The selectivity of the assay was checked by analyzing three independent blank human breast milk samples. The chromatograms of these blanks samples were compared with chromatograms obtained by analyzing the biological fluid samples spiked with TPM and chlorpromazine, the internal standard, and with other antiepileptic drugs: carbamazepine and phenytoin.

The solutions were prepared at a concentration of 20 µg/mL of each compound. TPM and chlorpromazine were well separated, with a resolution (R) value between both peaks of 5.20 (Figure 2). Carbamazepine and phenytoin run with the solvent line. Moreover, with a resolution (R) value between both peaks of 5.20 (Figure 2).

Table 1: Precision of Topiramate in human breast milk.

<table>
<thead>
<tr>
<th>Concentration (µg/mL)</th>
<th>RSD Intra-assay</th>
<th>RSD Inter-assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3</td>
<td>3.04</td>
<td>3.46</td>
</tr>
<tr>
<td>10.0</td>
<td>3.10</td>
<td>1.81</td>
</tr>
<tr>
<td>50.0</td>
<td>3.14</td>
<td>4.10</td>
</tr>
</tbody>
</table>

Application of the method

The developed method was linear between the concentrations range expected, precise, accurate, sensible, and selective for the quantitative determination of TPM in studied matrix: human breast milk. It is very important because TPM can produce severe damage to the fetus, and not always is possible that the epileptic woman change this drug when she is pregnant, because sometimes no other antiepileptic drug is effective in some people.

Using human breast milk we can estimate the drug quantity in baby blood, without the ethic aspects to withdrawal blood of them. It is possible to establish a relationship between the drug quantity in breast milk of epileptic woman with topiramate as her medication for the disease, and drug quantity in baby blood. These steps will be a continuation of this work, including another biological fluid studied for the disease, and dug quantity in baby blood. These steps will be a continuation of this work, including another biological fluid studied for the disease, and dug quantity in baby blood. That allows the quantitation of TPM in human breast milk with the aim of predict the drug concentration in the baby blood using a relationship between these levels. Of this way, it is not necessary to obtain blood from the baby to quantify the drug levels.

The most significant advantage of the present HPTLC method is this allows the quantitation of TPM in human breast milk with the aim of predict the drug concentration in the baby blood using a relationship between these levels. Of this way, it is not necessary to obtain blood from the baby to quantify the drug levels.

The chromatographic conditions are simple, the analysis requires a short period of time (HPTLC separation was obtained within twelve minutes), and the method allows for the analysis of many samples simultaneously with a very good accuracy, sensitivity and precision.

None method was founded by quantitative determination of TPM in breast milk.
Conflict of Interest Statement

The authors declare that they have no financial/commercial conflicts of interest.

Acknowledgements

The authors would like to thank the Research Council at the University of Concepción (Project UCO 12.01). This work is part of the Thesis of Master in Pharmaceutical Sciences (University of Concepción, Chile) of Miss Cristina Cifuentes.

References


